These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31240636)

  • 1. Transparency in Decision Modelling: What, Why, Who and How?
    Sampson CJ; Arnold R; Bryan S; Clarke P; Ekins S; Hatswell A; Hawkins N; Langham S; Marshall D; Sadatsafavi M; Sullivan W; Wilson ECF; Wrightson T
    Pharmacoeconomics; 2019 Nov; 37(11):1355-1369. PubMed ID: 31240636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.
    Carlson JJ; Walton SM; Basu A; Chapman RH; Campbell JD; McQueen RB; Pearson SD; Touchette DR; Veenstra D; Whittington MD; Ollendorf DA
    Pharmacoeconomics; 2019 Nov; 37(11):1321-1327. PubMed ID: 31485925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria.
    Feig C; Cheung KL; Hiligsmann M; Evers SMAA; Simon J; Mayer S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):223-232. PubMed ID: 28862060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results.
    Marks Y; Hoch JS; Heath A; Pechlivanoglou P
    Pharmacoeconomics; 2024 Jul; 42(7):783-795. PubMed ID: 38607519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.
    Wu EQ; Zhou ZY; Xie J; Metallo C; Thokala P
    Pharmacoeconomics; 2019 Nov; 37(11):1349-1354. PubMed ID: 31591672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.
    Philips Z; Bojke L; Sculpher M; Claxton K; Golder S
    Pharmacoeconomics; 2006; 24(4):355-71. PubMed ID: 16605282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
    Kent S; Becker F; Feenstra T; Tran-Duy A; Schlackow I; Tew M; Zhang P; Ye W; Lizheng S; Herman W; McEwan P; Schramm W; Gray A; Leal J; Lamotte M; Willis M; Palmer AJ; Clarke P
    Pharmacoeconomics; 2019 Nov; 37(11):1305-1312. PubMed ID: 31347104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Transparency in Decision Models: Current Issues and Potential Solutions.
    Tappenden P; Caro JJ
    Pharmacoeconomics; 2019 Nov; 37(11):1303-1304. PubMed ID: 31642021
    [No Abstract]   [Full Text] [Related]  

  • 12. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models.
    Hollman C; Paulden M; Pechlivanoglou P; McCabe C
    Pharmacoeconomics; 2017 Aug; 35(8):817-830. PubMed ID: 28488257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users.
    O'Flaherty M; Lloyd-Williams F; Capewell S; Boland A; Maden M; Collins B; Bandosz P; Hyseni L; Kypridemos C
    Health Technol Assess; 2021 May; 25(35):1-234. PubMed ID: 34076574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model Structuring for Economic Evaluations of New Health Technologies.
    Haji Ali Afzali H; Bojke L; Karnon J
    Pharmacoeconomics; 2018 Nov; 36(11):1309-1319. PubMed ID: 30030816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment.
    Desai B; Mattingly TJ; van den Broek RWM; Pham N; Frailer M; Yang J; Perfetto EM
    Value Health; 2020 Jun; 23(6):689-696. PubMed ID: 32540225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.